Nonalcoholic fatty liver disease - A multisystem disease?

World Journal of Gastroenterology

Volumn 22, Issue 43, 2016, Pages 9488-9505

  Mikolasevic, Ivana ^a   Milic, Sandra ^a   Wensveen, Tamara Turk ^a   Grgic, Ivana ^a   Jakopcic, Ivan ^b   Stimac, Davor ^a   Wensveen, Felix ^b   Orlic, Lidija ^a  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Cardiovascular disease; Chronic kidney disease; Diabetes mellitus type 2; Metabolic syndrome; Multisystem disease; Onalcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; INSULIN; SOMATOMEDIN C;

AORTA VALVE DISEASE; AORTIC VALVE SCLEROSIS; ARTERIAL WALL THICKNESS; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COLORECTAL CANCER; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; EPICARDIAL FAT; EPICARDIAL FAT THICKNESS; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; LIPID STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PSORIASIS; QTC INTERVAL; REVIEW; SLEEP DISORDERED BREATHING; SYSTEMIC DISEASE; ANIMAL; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84995877189     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i43.9488     Document Type: Review

References (173)

1. Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med 2015;5:7-13 [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7]
2. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-S64 [PMID: 25920090 DOI: 10.1016/j.jhep. 2014.12.012]
3. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis 2014;64:638-652 [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019]
4. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014;59:1174-1197 [PMID: 24002776 DOI: 10.1002/hep. 26717]
5. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-1953 [PMID: 18762907 DOI: 10.1007/s00125-008-1135-4]
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923 [PMID: 12668987 DOI: 10.1053/j.hep. 2003.50161]
7. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]
8. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-1350 [PMID: 20879883 DOI: 10.1056/NEJMra0912063]
9. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-1200 [PMID: 22408036 DOI: 10.1093/eurheartj/ehr453]
10. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
11. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602 [PMID: 20014114 DOI: 10.1002/hep. 23314]
12. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 2014;20:13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20. i37.13306]
13. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873 [PMID: 17006923 DOI: 10.1002/hep. 21327]
14. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554 [PMID: 25125077 DOI: 10.1002/hep. 27368]
15. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58:3017-3023 [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5]
16. Dunn MA, Behari J, Rogal SS, O'Connell MR, Furlan A, Aghayev A, Gumus S, Saul MI, Bae KT. Hepatic steatosis in diabetic patients does not predict adverse liver-related or cardiovascular outcomes. Liver Int 2013;33:1575-1582 [PMID: 23944954 DOI: 10.1111/liv. 12285]
17. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-240 [PMID: 16970951 DOI: 10.1016/j.atherosclerosis.2006.0 8.021]
18. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-1584 [PMID: 17461452 DOI: 10.3748/wjg.v13.i10.1579]
19. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009;50:1403-1411 [PMID: 19670414 DOI: 10.1002/hep. 23135]
20. Zhou YJ, Li YY, Nie YQ, Huang CM, Cao CY. Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 2012;13:153-160 [PMID: 22356310 DOI: 10.1111/j.1751-2980.2011.00571.x]
21. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011;343:d6891 [PMID: 22102439 DOI: 10.1136/bmj.d6891]
22. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646-650 [PMID: 22245962 DOI: 10.1016/j.cgh.2011.12.039]
23. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365 [PMID: 23175136 DOI: 10.1002/hep. 26156]
24. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL. Coronary artery disease and cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Gut 2011;60:1721-1727 [PMID: 21602530 DOI: 10.1136/gut.2011.242016]
25. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012;32:945-950 [PMID: 22299674 DOI: 10.1111/j.1478-3231.2011.02753.x]
26. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013;230:258-267 [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052]
27. Cobble M, Bale B. Carotid intima-media thickness: knowledge and application to everyday practice. Postgrad Med 2010;122:10-18 [PMID: 20107284 DOI: 10.3810/pgm.2010.01.2091]
28. Homma S, Hirose N, Ishida H, Ishii T, Araki G. Carotid plaque and intima-media thickness assessed by b-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke 2001;32:830-835 [PMID: 11283378 DOI: 10.1161/01. STR.32.4.830]
29. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intimamedia thickness: a systematic review and meta-analysis. Circulation 2007;115:459-467 [PMID: 17242284 DOI: 10.1161/CIRCULATIONAHA.106.628875]
30. Engström G, Melander O, Hedblad B. Carotid intima-media thickness, systemic inflammation, and incidence of heart failure hospitalizations. Arterioscler Thromb Vasc Biol 2009;29:1691-1695 [PMID: 19644052 DOI: 10.1161/ATVBAHA.109.193490]
31. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005;11:1848-1853 [PMID: 15793879 DOI: 10.3748/wjg.v11.i12.1848]
32. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204:521-525 [PMID: 18947828 DOI: 10.1016/j.athe]
33. Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. World J Gastroenterol 2009;15:4770-4774 [PMID: 19824109 DOI: 10.3748/wjg.15.4770]
34. Mohammadi A, Sedani HH, Ghasemi-Rad M. Evaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver disease. Vasc Health Risk Manag 2011;7:661-665 [PMID: 22140316 DOI: 10.2147/VHRM. S26011]
35. Colak Y, Karabay CY, Tuncer I, Kocabay G, Kalayci A, Senates E, Ozturk O, Doganay HL, Enc FY, Ulasoglu C, Kiziltas S. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2012;24:613-618 [PMID: 22495402 DOI: 10.1097/MEG.0b013e3283513f19]
36. Huang Y, Bi Y, Xu M, Ma Z, Xu Y, Wang T, Li M, Liu Y, Lu J, Chen Y, Huang F, Xu B, Zhang J, Wang W, Li X, Ning G. Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. Arterioscler Thromb Vasc Biol 2012;32:2321-2326 [PMID: 22814750]
37. Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010;28:1699-1707 [PMID: 20467324]
38. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29:1325-1330 [PMID: 16732016 DOI: 10.2337/dc06-0135]
39. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, Agladioglu K, Yeniova AO, Nazligul Y, Ertugrul DT. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2013;25:147-151 [PMID: 23085576 DOI: 10.1097/MEG.0b013e32835a58b1]
40. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis A, Stefanadis C. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010;23:1183-1189 [PMID: 20634799 DOI: 10.1038/ajh.2010.144]
41. Quinn U, Tomlinson LA, Cockcroft JR. Arterial stiffness. JRSM Cardiovasc Dis 2012;1:pii: cvd.2012.012024 [PMID: 24175072 DOI: 10.1258/cvd.2012.012024]
42. Işilak Z, Aparci M, Kardeşoǧlu E, Yiǧiner O, Uz O, Sildiroglu O, Ozmen N, Yalçin M, Cingözbay BY, Cebeci BS. Abnormal aortic elasticity in patients with liver steatosis. Diabetes Res Clin Pract 2010;87:44-50 [PMID: 19926158 DOI: 10.1016/j.diabres.2009.10.009]
43. Fotbolcu H, Yakar T, Duman D, Ozden K, Karaahmet T, Tigen K, Kurtoglu U, Dindar I. Aortic elastic properties in nonalcoholic fatty liver disease. Blood Press Monit 2010;15:139-145 [PMID: 20414104 DOI: 10.1097/MBP.0b013e328339e2c8]
44. Catena C, Bernardi S, Sabato N, Grillo A, Ermani M, Sechi LA, Fabris B, Carretta R, Fallo F. Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. Nutr Metab Cardiovasc Dis 2013;23:389-393 [PMID: 22796347 DOI: 10.1016/j.numecd.2012.05.007]
45. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196-203 [PMID: 21750929 DOI: 10.1007/s10620-011-1819-3]
46. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473-480 [PMID: 15981216 DOI: 10.1002/hep. 20781]
47. Iacobellis G, Barbarini G, Letizia C, Barbaro G. Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. Obesity (Silver Spring) 2014;22:332-336 [PMID: 24115757 DOI: 10.1002/oby.20624]
48. Granér M, Siren R, Nyman K, Lundbom J, Hakkarainen A, Pentikäinen MO, Lauerma K, Lundbom N, Adiels M, Nieminen MS, Taskinen MR. Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab 2013;98:1189-1197 [PMID: 23418318 DOI: 10.1210/jc.2012-3190]
49. Nelson MR, Mookadam F, Thota V, Emani U, Al Harthi M, Lester SJ, Cha S, Stepanek J, Hurst RT. Epicardial fat: an additional measurement for subclinical atherosclerosis and cardiovascular risk stratification? J Am Soc Echocardiogr 2011;24:339-345 [PMID: 21185148 DOI: 10.1016/j.echo.2010.11.008]
50. Cikim AS, Topal E, Harputluoglu M, Keskin L, Zengin Z, Cikim K, Ozdemir R, Aladag M, Yologlu S. Epicardial adipose tissue, hepatic steatosis and obesity. J Endocrinol Invest 2007;30:459-464 [PMID: 17646719]
51. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O'Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-2466 [PMID: 14581396 DOI: 10.1161/01. CIR.0000099542.57313. C5]
52. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, Haluzikova D, Bosanska L, Vokurka M, Svacina S, Haluzik M. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab 2006;91:4620-4627 [PMID: 16895955 DOI: 10.1210/jc.2006-1044# sthash.zIAcAzjw.dpuf]
53. Baker AR, Harte AL, Howell N, Pritlove DC, Ranasinghe AM, da Silva NF, Youssef EM, Khunti K, Davies MJ, Bonser RS, Kumar S, Pagano D, McTernan PG. Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun. N-terminal kinase mediated inflammation in patients with coronary artery disease. J Clin Endocrinol Metab 2009;94:261-267 [PMID: 18984670 DOI: 10.1210/jc.2007-2579]
54. Nakazato R, Dey D, Cheng VY, Gransar H, Slomka PJ, Hayes SW, Thomson LE, Friedman JD, Min JK, Berman DS. Epicardial fat volume and concurrent presence of both myocardial ischemia and obstructive coronary artery disease. Atherosclerosis 2012;221:422-426 [PMID: 22305262 DOI: 10.1016/j.atherosclerosis.2011.12. 018]
55. Khawaja T, Greer C, Chokshi A, Chavarria N, Thadani S, Jones M, Schaefle K, Bhatia K, Collado JE, Shimbo D, Einstein AJ, Schulze PC. Epicardial fat volume in patients with left ventricular systolic dysfunction. Am J Cardiol 2011;108:397-401 [PMID: 21565323 DOI: 10.1016/j.amjcard.2011.03.058]
56. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008;52:1793-1799 [PMID: 19022158 DOI: 10.1016/j.jacc.2008.07.062]
57. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 2008;201:1-7 [PMID: 18561934 DOI: 10.1016/j.atherosclerosi]
58. Santos RD, Nasir K, Orakzai R, Meneghelo RS, Carvalho JA, Blumenthal RS. Relation of uric acid levels to presence of coronary artery calcium detected by electron beam tomography in men free of symptomatic myocardial ischemia with versus without the metabolic syndrome. Am J Cardiol 2007;99:42-45 [PMID: 17196459 DOI: 10.1016/j.amjcard.2006.07.057]
59. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254:393-400 [PMID: 20093511 DOI: 10.1148/radiol.09090769]
60. Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010;55:1752-1760 [PMID: 19688595 DOI: 10.1007/s10620-009-0935-9]
61. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int 2007;27:891-894 [PMID: 17696926 DOI: 10.1111/j.1478-3231.2007.01531.x]
62. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40:949-955 [PMID: 17063117 DOI: 10.1097/01.mcg.0000225668.53673.e6]
63. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, Fabris B, Sechi LA. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009;19:646-653 [PMID: 19278843]
64. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:1724-1745 [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724]
65. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol 2010;30:1855-1860 [PMID: 20539015 DOI: 10.1161/ATVBAHA.110.207340]
66. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Λ-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 2012;32:830-835 [PMID: 22223732 DOI: 10.1161/ATVBAHA.111.240457]
67. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, Zoppini G, Mantovani W, Barbieri E, Byrne CD. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013;8:e57183 [PMID: 23451184 DOI: 10.1371/journal.pone.0057183]
68. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, Morani G, Vassanelli C, Bonora E. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013;125:301-309 [PMID: 23596966 DOI: 10.1042/CS20130036]
69. Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One 2015;10:e0142937 [PMID: 26571029 DOI: 10.1371/journal.pone.0142937]
70. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-1894 [PMID: 2040041 DOI: 10.1161/01. CIR.83.6.1888]
71. Robbins J, Nelson JC, Rautaharju PM, Gottdiener JS. The association between the length of the QT interval and mortality in the Cardiovascular Health Study. Am J Med 2003;115:689-694 [PMID: 14693320 DOI: 10.1016/j.amjmed.2003.07.014]
72. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, Mantovani A, Zoppini G, Bonora E, Barbieri E, Byrne CD. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2014;24:663-669 [PMID: 24594085 DOI: 10.1016/j.numecd.2014.01.005]
73. Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 2014;9:e88371 [PMID: 24505484 DOI: 10.1371/journal.pone.0088371]
74. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol 2011;54:1020-1029 [PMID: 21145850 DOI: 10.1016/j.jhep. 2010.11.007]
75. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012;27:420-428 [PMID: 22596186 DOI: 10.1097/HCO.0b013e328354829c]
76. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014;20:8407-8415 [PMID: 25024598 DOI: 10.3748/wjg.v20.i26.8407]
77. Krivis AF, Rabb JM. Cuprous complexes formed with isonicotinic hydrazide. Science 1969;164:1064-1065 [PMID: 4976919 DOI: 10.4330/wjc.v6.i6.462]
78. Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol 2015;7:1325-1336 [PMID: 26052378 DOI: 10.4254/wjh.v7.i10.1325]
79. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013;227:429-436 [PMID: 23419204 DOI: 10.1016/j.atherosclerosis.2013.01.022]
80. Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010;67:665-670 [PMID: 20496475 DOI: 10.1203/PDR.0b013e3181da4798]
81. Alkhouri N, Carter-Kent C, Elias M, Feldstein AE. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol 2011;6:305-314 [PMID: 22162978 DOI: 10.2217/clp. 11.19]
82. da Luz PL, Favarato D, Faria-Neto JR, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo) 2008;63:427-432 [PMID: 18719750 DOI: 10.1590/S1807-59322008000400003]
83. Gutiérrez-Grobe Y, Gavilanes-Espinar JG, Masso-Rojas FA, Sánchez-Valle V, Páez-Arenas A, Ponciano-Rodríguez G, Chávez-Tapia NC, Uribe M, Méndez-Sánchez N. Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells. Ann Hepatol 2013;12:908-914 [PMID: 24114821]
84. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013;167:1109-1117 [PMID: 23141876 DOI: 10.1016/j.ijcard.2012.09.085]
85. Akin L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmali F, Mazicioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr 2013;102:e107-e113 [PMID: 23190373 DOI: 10.1111/apa.12099]
86. Hashizume H, Sato K, Yamazaki Y, Horiguchi N, Kakizaki S, Mori M. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts. Acta Med Okayama 2013;67:45-53 [PMID: 23439508]
87. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 2008;14:72-81 [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003]
88. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54 [PMID: 15239085 DOI: 10.1002/hep. 20280]
89. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33 [PMID: 14551151 DOI: 10.1161/01. ATV.0000099786.99623]
90. Li XL, Sui JQ, Lu LL, Zhang NN, Xu X, Dong QY, Xin YN, Xuan SY. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis 2016;15:53 [PMID: 26965314 DOI: 10.1186/s12944-016-0221-8]
91. Petta S, Valenti L, Marchesini G, Di Marco V, Licata A, Cammà C, Barcellona MR, Cabibi D, Donati B, Fracanzani A, Grimaudo S, Parrinello G, Pipitone RM, Torres D, Fargion S, Licata G, Craxì A. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One 2013;8:e74089 [PMID: 24069270]
92. Paré G, Ridker PM, Rose L, Barbalic M, Dupuis J, Dehghan A, Bis JC, Benjamin EJ, Shiffman D, Parker AN, Chasman DI. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci. PLoS Genet 2011;7:e1001374 [PMID: 21533024 DOI: 10.1371/journal]
93. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 2011;7:456-465 [PMID: 21556019 DOI: 10.1038/nrendo.2011.72]
94. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395 [PMID: 15565570]
95. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, Méndez-Sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol 2014;13:166-178 [PMID: 24552858]
96. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-1145 [PMID: 16108839]
97. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192 [PMID: 11266382]
98. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110 [PMID: 2227807]
99. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231 [PMID: 11961152]
100. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138 [PMID: 15629518]
101. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a communitybased cohort study. Am J Gastroenterol 2010;105:1567-1573 [PMID: 20145609 DOI: 10.1038/ajg.2010.18]
102. Miele L, Bosetti C, Turati F, Rapaccini G, Gasbarrini A, La Vecchia C, Boccia S, Grieco A. Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk. Gastroenterol Res Pract 2015;2015:570356 [PMID: 26074956 DOI: 10.1155/2015/570356]
103. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-265 [PMID: 15017611]
104. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men. Role of visceral adipose tissue. Diabet Med 2005;22:1354-1358 [PMID: 16176196]
105. Tamura Y, Tanaka Y, Sato F, Choi JB, Watada H, Niwa M, Kinoshita J, Ooka A, Kumashiro N, Igarashi Y, Kyogoku S, Maehara T, Kawasumi M, Hirose T, Kawamori R. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2005;90:3191-3196 [PMID: 15769987]
106. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010; (1): CD007340 [PMID: 20091629 DOI: 10.1002/14651858. CD007340.pub2]
107. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diabetes Care 2007;30:707-712 [PMID: 17327345]
108. Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med 2009;26:1235-1241 [PMID: 20002475 DOI: 10.1111/j.1464-5491.2009.02839.x]
109. Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008;7:95-96 [PMID: 18249166 DOI: 10.1016/j.cmet.2007.12.009]
110. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008;7:125-134 [PMID: 18249172 DOI: 10.1016/j.cmet.2007.11.013]
111. Taniguchi CM, Kondo T, Sajan M, Luo J, Bronson R, Asano T, Farese R, Cantley LC, Kahn CR. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 2006;3:343-353 [PMID: 16679292]
112. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O' Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest 2009;119:315-322 [PMID: 19164855 DOI: 10.1172/JCI37432]
113. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11-18 [PMID: 19656312 DOI: 10.1111/j.1467-789X.2009.00623.x]
114. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 2007;293:E1118-E1128 [PMID: 17666485]
115. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 2009;29:1575-1591 [PMID: 19114551 DOI: 10.1128/MCB.01300-08]
116. Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S, Glasner A, Mendrila D, Štimac D, Wunderlich FT, Brüning JC, Mandelboim O, Polić B. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 2015;16:376-385 [PMID: 25729921 DOI: 10.1038/ni.3120]
117. Wensveen FM, Valentić S, Šestan M, Turk Wensveen T, Polić B. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. Eur J Immunol 2015;45:2446-2456 [PMID: 26220361 DOI: 10.1002/eji.201545502]
118. Wensveen FM, Valentić S, Šestan M, Wensveen TT, Polić B. Interactions between adipose tissue and the immune system in health and malnutrition. Semin Immunol 2015;27:322-333 [PMID: 26603491 DOI: 10.1016/j.smim.2015.10.006]
119. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905 [PMID: 15795412]
120. Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Méndez-Sánchez N. Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014;9:148-158 [PMID: 25514910]
121. Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci 2016;17:562 [PMID: 27089331 DOI: 10.3390/ijms17040562]
122. Musso G, Tabibian JH, Charlton M. Chronic kidney disease (CKD) and NAFLD: time for awareness and screening. J Hepatol 2015;62:983-984 [PMID: 25529627 DOI: 10.1016/j.jhep. 2014.11.044]
123. Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol 2016;13:196-205 [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3]
124. Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One 2014;9:e88569 [PMID: 24520400 DOI: 10.1371/journal.pone.0088569]
125. Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014;98:216-221 [PMID: 24621538 DOI: 10.1097/TP.0000000000000048]
126. Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539 [PMID: 24729784 DOI: 10.1155/2014/847539]
127. Casoinic F, Sâmpelean D, Bǎdǎu C, Prunǎ L. Nonalcoholic fatty liver disease - a risk factor for microalbuminuria in type 2 diabetic patients. Rom J Intern Med 2009;47:55-59 [PMID: 19886070]
128. Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ, Oh KW, Lee WY, Jin W. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 2010;40:437-442 [PMID: 19460054 DOI: 10.1111/j.1445-5994.2009.01979.x]
129. Ahn AL, Choi JK, Kim MN, Kim SA, Oh EJ, Kweon HJ, Cho DY. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med 2013;34:199-205 [PMID: 23730487 DOI: 10.4082/kjfm.2013.34.3.199]
130. Manco M, Ciampalini P, DeVito R, Vania A, Cappa M, Nobili V. Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatr Nephrol 2009;24:1211-1217 [PMID: 19242728 DOI: 10.1007/s00467-009-1134-9]
131. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis 2010;20:583-590 [PMID: 19699624 DOI: 10.1016/j.numecd.2009.05.012]
132. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-2171 [PMID: 20724519 DOI: 10.2215/CJN.05050610]
133. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010;59:1327-1330 [PMID: 20096896 DOI: 10.1016/j.metabol.2009.12.012]
134. Mikolasevic I, Racki S, Bubic I, Jelic I, Stimac D, Orlic L. Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney Blood Press Res 2013;37:305-310 [PMID: 24029696 DOI: 10.1159/000350158]
135. Barshop NJ, Francis CS, Schwimmer JB, Lavine JE. Nonalcoholic fatty liver disease as a comorbidity of childhood obesity. Ped Health 2009;3:271-281 [PMID: 20556232]
136. Lee DH, Jacobs DR, Gross M, Steffes M. Serum gammaglutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2005;51:1185-1191 [PMID: 15890893]
137. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007;53:71-77 [PMID: 17110470]
138. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19:1564-1570 [PMID: 18385424 DOI: 10.1681/ASN.2007101155]
139. Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, Jung E, Kim WS. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008;57:569-576 [PMID: 18328362 DOI: 10.1016/j.metabol.2007.11.022]
140. Jia G, Di F, Wang Q, Shao J, Gao L, Wang L, Li Q, Li N. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. PLoS One 2015;10:e0142808 [PMID: 26566287 DOI: 10.1371/journal.pone.0142808]
141. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliǧadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680 [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680]
142. Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S, Khedmat H, Amin M, Zali MR, Alavian SM. Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation. Hepat Mon 2013;13:e7382 [PMID: 23914227 DOI: 10.5812/hepatmon. 7382]
143. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009;5:677-689 [PMID: 19935815 DOI: 10.1038/nrneph.2009.173]
144. Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol 2010;21:406-412 [PMID: 20150538 DOI: 10.1681/ASN.2009080820]
145. Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015;127:355-362 [PMID: 25412597 DOI: 10.1007/s00508-014-0661-y]
146. Allen AM, Kim WR, Heimbach JK, Rule AD. Reply to: "Chronic kidney disease (CKD) and NAFLD: time for awareness and screening". J Hepatol 2015;62:984-985 [PMID: 25529624 DOI: 10.1016/j.jhep. 2014.12.019]
147. Shen H, Lipka S, Kumar A, Mustacchia P. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol 2014;5:440-446 [PMID: 25436123 DOI: 10.3978/j.issn. 2078-6891.2014.061]
148. Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, Chen YP, Wong DK, Yuen MF, Zheng MH. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep 2014;41:2989-2997 [PMID: 24449368 DOI: 10.1007/s11033-014-3157-y]
149. You J, Huang S, Huang GQ, Zhu GQ, Ma RM, Liu WY, Shi KQ, Guo GL, Chen YP, Braddock M, Zheng MH. Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis. Medicine (Baltimore) 2015;94:e479 [PMID: 25654388 DOI: 10.1097/MD.0000000000000479]
150. Stadlmayr A, Aigner E, Steger B, Scharinger L, Lederer D, Mayr A, Strasser M, Brunner E, Heuberger A, Hohla F, Steinwendner J, Patsch W, Datz C. Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia. J Intern Med 2011;270:41-49 [PMID: 21414047 DOI: 10.1111/j.1365-2796.2011.02377.x]
151. Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Won KH, Jin W. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010;25:562-567 [PMID: 20074156 DOI: 10.1111/j.1440-1746.2009.06117.x]
152. Lee YI, Lim YS, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol 2012;27:91-95 [PMID: 21679251 DOI: 10.1111/j.1440-1746.2011.06816.x]
153. Wong VW, Wong GL, Tsang SW, Fan T, Chu WC, Woo J, Chan AW, Choi PC, Chim AM, Lau JY, Chan FK, Sung JJ, Chan HL. High prevalence of colorectal neoplasm in patients with nonalcoholic steatohepatitis. Gut 2011;60:829-836 [PMID: 21339204 DOI: 10.1136/gut.2011.237974]
154. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015;7:315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315]
155. Ganzetti G, Campanati A, Molinelli E, Offidani A. Psoriasis, nonalcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol 2016;8:120-131 [PMID: 26981209 DOI: 10.4330/wjc.v8.i2.120]
156. Krueger G, Ellis CN. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:S94-S100 [PMID: 15968269]
157. Rácz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med 2009;11:e38 [PMID: 20003607 DOI: 10.1017/S146239940900129X]
158. Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci 2016;17:217 [PMID: 26861300 DOI: 10.3390/ijms17020217]
159. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51:758-764 [PMID: 19560226 DOI: 10.1016/j.jhep. 2009.04.020]
160. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012;53:190-197 [PMID: 22672067 DOI: 10.1111/j.1440-0960.2012.00905.x]
161. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2016;30:282-287 [PMID: 26537011 DOI: 10.1111/jdv. 13456]
162. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 2015;40:722-727 [PMID: 25958919 DOI: 10.1111/ced.12672]
163. Candia R, Ruiz A, Torres-Robles R, Chávez-Tapia N, Méndez-Sánchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015;29:656-662 [PMID: 25418531 DOI: 10.1111/jdv. 12847]
164. Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne) 2015;2:1 [PMID: 25654080 DOI: 10.3389/fmed.2015.00001]
165. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS, Grinspoon SK. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011;96:E146-E150 [PMID: 21047923 DOI: 10.1210/jc.2010-1170]
166. Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-tosevere chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011;21:916-920 [PMID: 21983007 DOI: 10.1684/ejd.2011.1548]
167. Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, Benedetti A, Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013;48:839-846 [PMID: 23065020 DOI: 10.1007/s00535-012-0678-9]
168. Feagins LA, Flores A, Arriens C, Park C, Crook T, Reimold A, Brown G. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol 2015;27:1154-1160 [PMID: 26148245 DOI: 10.1097/MEG.0000000000000421]
169. Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol 2015;52:117-123 [PMID: 26039829 DOI: 10.1590/S0004-28032015000200008]
170. Zueff LF, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012;39:341-347 [PMID: 21898634 DOI: 10.1002/uog.10084]
171. Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009;24:243-247 [PMID: 19215335 DOI: 10.1111/j.1440-1746.2008.05740.x]
172. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010;9:402-409 [PMID: 21057159]
173. Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev 2013;14:417-431 [PMID: 23387384 DOI: 10.1111/obr.12020]